Tirzepatide Dose Escalation Chart
The FDA-labeled titration ladder from 2.5 mg to 15 mg, week by week, with the maintenance dose patients land on at each tier.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
Tirzepatide is FDA-approved as Mounjaro (type 2 diabetes, 2022) and Zepbound (chronic weight management, 2023). Unlike semaglutide, it activates both GLP-1 and GIP receptors, which is the basis for its larger weight-loss effect in head-to-head trials. The titration schedule is identical for both indications and follows a 4-week-per-step pattern up to a 15 mg ceiling.
Tirzepatide at a Glance
| Indications (FDA-labeled) | Type 2 diabetes (Mounjaro), chronic weight management (Zepbound) |
|---|---|
| Route | Subcutaneous injection — abdomen, thigh, or upper arm |
| Frequency | Once weekly, same day each week |
| Max dose | 15 mg/week |
| Total titration time | Up to 24 weeks to reach 15 mg (4 weeks per step) |
| Common maintenance doses | 5 mg, 10 mg, 12.5 mg, or 15 mg — many patients stop at an intermediate tier |
| FDA status | FDA-approved (Mounjaro 2022, Zepbound 2023). Compounded versions also available. |
Tirzepatide Dose Escalation Schedule
| Weeks | Dose | Notes |
|---|---|---|
| Weeks 1–4 | 2.5 mg | Starting dose. Tolerability dose — not for weight or glycemic effect. |
| Weeks 5–8 | 5 mg | First effective dose. Many patients hold here if tolerating well and meeting goals. |
| Weeks 9–12 | 7.5 mg | Intermediate step. Increase by 2.5 mg every 4 weeks as tolerated. |
| Weeks 13–16 | 10 mg | Common maintenance dose for both diabetes and weight loss. |
| Weeks 17–20 | 12.5 mg | Step toward maximum. Many patients hold here. |
| Week 21+ | 15 mg | Maximum dose. Continue indefinitely if tolerated. |
Not all patients need to reach the maximum dose. Per the FDA label, if a 5 mg dose produces adequate response, patients can stay there. Increase only if additional benefit is needed and the current dose is well tolerated.
Tirzepatide Dosing by Use Case
Commonly cited protocols vary by what Tirzepatide is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| Chronic weight management (Zepbound) | 5–15 mg | Once weekly | Continuous, indefinite | SURMOUNT-1 trial showed average ~21% body weight loss at 15 mg over 72 weeks. |
| Type 2 diabetes (Mounjaro) | 2.5–15 mg | Once weekly | Continuous, indefinite | Adjust based on HbA1c response and tolerability. |
| Compounded tirzepatide (off-label) | Same titration as labeled | Once weekly | Continuous | Follow the same titration schedule. Compounded versions are not FDA-approved. |
Stacking Tirzepatide
Tirzepatide is not commonly stacked with other GLP-1s — running it alongside semaglutide is not standard practice and risks compounded GI side effects. Some clinics combine it with AOD-9604 or 5-Amino-1MQ for additional fat-loss effects, but the evidence base is thin.
Tirzepatide carries the same FDA black box warning as semaglutide for thyroid C-cell tumors, with similar GI side effects amplified by the additional GIP activity.
- •FDA black box warning: thyroid C-cell tumors in rodent studies. Contraindicated with personal or family history of medullary thyroid carcinoma or MEN 2.
- •Most common side effects: nausea, diarrhea, decreased appetite, vomiting, constipation. GI burden tends to be higher than semaglutide at equivalent weight-loss tiers.
- •Pancreatitis is a rare but serious adverse event — discontinue and seek evaluation for severe abdominal pain.
- •Hypoglycemia risk is low with tirzepatide alone but increases when combined with insulin or sulfonylureas.
- •Not approved for type 1 diabetes.
- •Personal or family history of medullary thyroid carcinoma
- •Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- •Active severe gastroparesis (relative contraindication)
- •Pregnancy or planning to become pregnant
Tirzepatide Dosing FAQ
The FDA label specifies 2.5 mg increments every 4 weeks. Larger jumps are associated with higher GI side-effect rates and treatment discontinuation. Most providers will hold a step longer rather than skip a step.
No. Per Eli Lilly's prescribing guidance, many patients find their effective maintenance dose at 5 mg, 10 mg, or 12.5 mg. Climb only as high as needed for benefit; the side-effect burden generally increases with each step.
In head-to-head trial data (SURPASS-2 and SURMOUNT-class evidence), tirzepatide produces greater weight loss on average than semaglutide. The dual GLP-1/GIP mechanism is the proposed reason. Side-effect profiles are broadly similar but tirzepatide tends to drive more GI symptoms at equivalent weight-loss tiers.
Per the FDA label: if you miss a dose, take it as soon as possible within 4 days. If more than 4 days have passed, skip the missed dose and resume on your normal weekly schedule. Do not take two doses within 3 days of each other.
Sources
Related Dosage Charts
Want the full Tirzepatide guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for Tirzepatide therapy.
See Tirzepatide guideMedical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.